argenex SE (NASDAQ:ARGX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

argenex SE (NASDAQ:ARGX) has been given a consensus recommendation of “Moderate Buy” by the twenty-four ratings firms that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $1,054.1111.

Several analysts have issued reports on the company. Wall Street Zen raised argenex from a “hold” rating to a “buy” rating in a research report on Saturday. Wells Fargo & Company upped their price objective on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research note on Monday, June 1st. Royal Bank Of Canada raised their price objective on argenex from $945.00 to $1,025.00 and gave the company an “outperform” rating in a research report on Friday. Guggenheim lifted their target price on argenex from $1,135.00 to $1,185.00 and gave the company a “buy” rating in a research note on Friday. Finally, Citizens Jmp reduced their target price on shares of argenex from $944.00 to $932.00 and set a “market outperform” rating for the company in a report on Friday.

More argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx agreed to acquire Forte Biosciences (NASDAQ: FBRX) for $77 per share in cash, representing an equity value of approximately $2.2 billion and a 41% premium to Forte’s prior closing price. The transaction gives argenx full ownership of FB102, an experimental autoimmune therapy. argenx acquisition announcement
• Positive Sentiment: FB102’s Phase 1b data in vitiligo and celiac disease reportedly support CD122 biology and a potential “pipeline-in-a-product” opportunity targeting pathogenic T-cell and NK-cell activity in diseases with significant unmet need. The acquisition broadens argenx’s immunology pipeline beyond its existing portfolio. argenx Forte acquisition details
• Positive Sentiment: Analyst sentiment remains supportive in parts of the market: Robert W. Baird raised its price target to $932, while HC Wainwright increased its earnings estimates. A separate Oppenheimer report had previously lifted its target to $1,037.
• Neutral Sentiment: Baird maintained a “neutral” rating despite the higher target, implying that the acquisition’s long-term value is not yet fully reflected in near-term expectations. Baird price target report
• Negative Sentiment: The all-cash $2.2 billion transaction represents a substantial capital commitment for a clinical-stage asset. Investors may be concerned about integration costs, future development spending and the risk that FB102’s early-stage results do not translate into successful late-stage trials or commercialization. One analysis consequently rated the stock “Hold.” Forte and argenx investment analysis

argenex Stock Performance

Shares of ARGX opened at $888.82 on Tuesday. The company has a 50 day moving average price of $870.53 and a 200-day moving average price of $815.82. argenex has a fifty-two week low of $590.78 and a fifty-two week high of $953.58. The stock has a market capitalization of $55.60 billion, a PE ratio of 34.13, a PEG ratio of 1.21 and a beta of 0.45.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.86 by $1.46. The company had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 43.59%. Equities research analysts forecast that argenex will post 26.95 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Abound Wealth Management lifted its position in argenex by 3,200.0% during the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock valued at $28,000 after acquiring an additional 32 shares during the last quarter. Sound Income Strategies LLC purchased a new position in argenex in the fourth quarter worth $28,000. Whipplewood Advisors LLC purchased a new position in argenex in the first quarter worth $28,000. Eastern Bank acquired a new position in shares of argenex during the second quarter worth $32,000. Finally, Sunbelt Securities Inc. acquired a new position in shares of argenex during the third quarter worth $36,000. Institutional investors own 60.32% of the company’s stock.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.